Daily Dose - Mar 20th, 2026
Daily Dose |
View online
March 20, 2026
AstraZeneca plans commercial cell therapy manufacturing, R&D hub in Shanghai
As part of its $15 billion investment in China, the drugmaker intends to become the first global biopharma company with end-to-end cell therapy capabilities in the country.
Read More
Celltrion signs biologics CMO deal, says backlog tops $680M
The agreement adds to rising global demand for CDMO partnerships and may drive further capacity expansion, according to the company.
Read More
SK pharmteco commits $100M to expand viral vector business
The investment supports a three-unit strategy spanning small molecules, peptides, and advanced therapies at sites in the U.S. and France.
Read More
